The immunomodulatory benzodiazepine Bz-423 inhibits B-cell proliferation by targeting c-Myc protein for rapid and specific degradation

Cancer Research

Volumn 66, Issue 3, 2006, Pages 1775-1782

  Sundberg, Thomas B ^a   Ney, Gina M ^a   Subramanian, Chitra ^b   Opipari Jr , Anthony W ^a   Glick, Gary D ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE; BENZODIAZEPINE; BZ 423; GLYCOGEN SYNTHASE KINASE; THREONINE; UNCLASSIFIED DRUG;

ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG INHIBITION; DRUG SENSITIVITY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IMMUNOMODULATION; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN DEGRADATION; RESPIRATORY CHAIN;

B-LYMPHOCYTES; BENZODIAZEPINES; BIOGENIC POLYAMINES; BURKITT LYMPHOMA; CELL CYCLE PROTEINS; CELL GROWTH PROCESSES; HUMANS; LYMPHOCYTE ACTIVATION; MITOCHONDRIAL PROTON-TRANSLOCATING ATPASES; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTO-ONCOGENE PROTEINS C-MYC; SUPEROXIDES;

EID: 32944455992     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-3476     Document Type: Article

References (50)

1. Pelengaris S, Khan M, Evan G. c-MYC: more than just a matter of life and death. Nat Rev Cancer 2002;2:764-6.
2. Atchley WR, Fitch WM. Myc and Max: molecular evolution of a family of proto-oncogene products and their dimerization partner. Proc Natl Acad Sci U S A 1995;92:10217-21.
3. Coller HA, Grandori C, Tamayo P, et al. Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion. Proc Natl Acad Sci U S A 2000;97:3260-5.
4. Gartel AL, Ye X Goufman E, et al. Myc represses the p21(WAF1/CIP1) promoter and interacts with Sp1/Sp3. Proc Natl Acad Sci U S A 2001;98:45105.
5. Nesbit CE, Tersak JM, Prochownik EV. MYC oncogenes and human neoplastic disease. Oncogene 1999;18:3004-16.
6. Dang CV. c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol 1999;19:1-11.
7. Battey J, Moulding C, Taub R, et al. The human c-myc oncogene: structural consequences of translocation into the IgH locus in Burkitt lymphoma. Cell 1983;34:779-87.
8. Smith JB, Wickstrom E. Inhibition of tumorigenesis in a murine B-cell lymphoma transplant model by c-Myc complementary oligonucleotides. Adv Exp Med Biol 1998;451:17-22.
9. Huang Y, Snyder R, Kligshteyn M, Wickstrom E. Prevention of tumor formation in a mouse model of Burkitt's lymphoma by 6 weeks of treatment with anti-c-myc DNA phosphorothioate. Mol Med 1995;1:647-58.
10. Blatt NB, Bednarski JJ, Warner RE, et al. Benzodiazepine-induced superoxide signals B cell apoptosis: mechanistic insight and potential therapeutic utility. J Clin Invest 2002;110:1123-32.
11. Boitano A. Ellman JA, Glick GD, Opipari AW, Jr. The proapoptotic benzodiazepine Bz-423 affects the growth and survival of malignant B cells. Cancer Res 2003;63:6870-6.
12. Bednarski JJ, Warner RE, Rao T, et al. Attenuation of autoimmune disease in Fas-deficient mice by treatment with a cytotoxic benzodiazepine. Arthritis Rheum 2003;48:757-66.
13. Johnson KM, Chen X, Boitano A, Swenson L, Opipari AW, Jr., Glick GD. Identification and validation of the mitochondrial F(1)F(0)-ATPase as the molecular target of the immunomodulatory benzodiazepine bz-423. Chem Biol 2005;12:485-96.
14. Bunin BA, Plunkett MJ, Ellman JA. The combinatorial synthesis and chemical and biological evaluation of a 1,4-benzodiazepine library. Proc Natl Acad Sci U S A 1994;91:4708-12.
15. Djurhuus R. Ornithine decarboxylase (EC 4.1.1.17) assay based upon the retention of putrescine by a strong cation-exchange paper. Anal Biochem 1981;113:352-5.
16. Nitta T, Igarashi K, Yamamoto N. Polyamine depletion induces apoptosis through mitochondria-mediated pathway. Exp Cell Res 2002;276:120-8.
17. Chang BD, Watanabe K, Broude EV et al. Effects of p21Waf1/Cip1/Sdi1 on cellular gene expression: implications for carcinogenesis, senescence, and age-related diseases. Proc Natl Acad Sci U S A 2000;97:4291-6.
18. Voigt W. Sulforhodamine B assay and chemosensitivity. Methods Mol Med 2005;110:39-8.
19. An S, Park MJ, Park IC, Hong SI, Knox K. Procaspase-3 and its active large subunit localized in both cytoplasm and nucleus are activated following application of apoptotic stimulus in Ramos-Burkitt lymphoma B cells. Int J Mol Med 2003;12:311-7.
20. Coffino P. Regulation of cellular polyamines by antizyme. Nat Rev Mol Cell Biol 2001;2:188-94.
21. Thomas T, Thomas TJ. Polyamines in cell growth and cell death: molecular mechanisms and therapeutic applications. Cell Mol Life Sci 2001;58:244-58.
22. Bello-Fernandez C, Packham G, Cleveland JL. The ornithine decarboxylase gene is a transcriptional target of c-Myc. Proc Natl Acad Sci U S A 1993;90:7804-8.
23. Murray AW. Recycling the cell cycle: cyclins revisited. Cell 2004;116:221-4.
24. 1-phase progression. Genes Dev 1999;13:1501-12.
25. Fernandez PC, Frank SR, Wang L, et al. Genomic targets of the human c-Myc protein. Genes Dev 2003;17:1115-29.
26. Cobrinik D. Pocket proteins and cell cycle control. Oncogene 2005;24:2796-809.
27. 1-S cyclin-dependent kinases. J Biol Chem 1997;272:12738-46.
28. Banerji L, Glassford J, Lea NC, Thomas NS, Klaus GG, Lam EW. BCR signals target p27(Kip1) and cyclin D2 via the PI3-K signalling pathway to mediate cell cycle arrest and apoptosis of WEHI 231 B cells. Oncogene 2001;20:7352-67.
29. 1 phase by specific inhibition of CDK2 kinase activity. Exp Cell Res 1998;245:8-18.
30. Zheng Y, Shi Y, Tian C, et al. Essential role of the voltage-dependent anion channel (VDAC) in mitochondrial permeability transition pore opening and cytochrome c release induced by arsenic trioxide. Oncogene 2004;23:1239-47.
31. Luscher B. Function and regulation of the transcription factors of the Myc/Max/Mad network. Gene 2001;277:1-14.
32. Hu X, Bies J, Wolff L. Interferon β increases c-Myc proteolysis in mouse monocyte/macrophage leukemia cells. Leuk Res 2005;29:307-14.
33. Chandramohan V, Jeay S, Pianetti S, Sonenshein GE, Reciprocal control of Forkhead box O 3a and c-Myc via the phosphatidylinositol 3-kinase pathway coordinately regulates p27Kip1 levels. J Immunol 2004;172:5522-7.
34. Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, Nevins JR. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev 2000;14:2501-14.
35. Gregory MA, Hann SR. c-Myc proteolysis by the ubiquitin-proteasome pathway: stabilization of c-Myc in Burkitt's lymphoma cells. Mol Cell Biol 2000;20:2423-35.
36. Kamemura K, Hayes BK, Comer FI, Hart GW. Dynamic interplay between O-glycosylation and O-phosphorylation of nucleocytoplasmic proteins: alternative glycosylation/phosphorylation of THR-58, a known mutational hot spot of c-Myc in lymphomas, is regulated by mitogens. J Biol Chem 2002;277:19229-35.
37. Gregory MA, Qi Y, Hann SR. Phosphorylation by glycogen synthase kinase-3 controls c-myc proteolysis and subnuclear localization. J Biol Chem 2003;278:51606-12,
38. Rajkumar SV, Richardson PG, Hideshima T, Anderson KC. Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 2005;23:630-9.
39. Coghlan MP, Culbert AA, Cross DA, et al. Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem Biol 2000;7:793-803.
40. Prochownik EV. c-Myc as a therapeutic target in cancer. Expert Rev Anticancer Ther 2004;4:289-302.
41. Hermeking H. The MYC oncogene as a cancer drug target. Curr Cancer Drug Targets 2003;3:163-75.
42. Berg T, Cohen SB, Desharnais J, et al. Small-molecule antagonists of Myc/Max dimerization inhibit Myc-induced transformation of chicken embryo fibroblasts. Proc Natl Acad Sci U S A 2002;99:3830-5.
43. Yin X, Giap C, Lazo JS, Prochownik EV. Low molecular weight inhibitors of Myc-Max interaction and function. Oncogene 2003;22:6151-9.
44. Oster SK, Mao DY, Kennedy J, Penn LZ. Functional analysis of the N-terminal domain of the Myc oncoprotein. Oncogene 2003;22:1998-2010.
45. Yeh E, Cunningham M, Arnold H, et al. A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat Cell Biol 2004;6:308-18.
46. Chou TY, Dang CV, Hart GW. Glycosylation of the c-Myc transactivation domain. Proc Natl Acad Sci U S A 1995;92:4417-21.
47. Ang XL, Wade Harper J. SCF-mediated protein degradation and cell cycle control. Oncogene 2005;24:2860-70.
48. Li YP, Chen Y, Li AS, Reid MB. Hydrogen peroxide stimulates ubiquitin-conjugating activity and expression of genes for specific E2 and E3 proteins in skeletal muscle myotubes. Am J Physiol Cell Physiol 2003;285: C806-12.
49. Jahngen-Hodge J, Obin MS, Gong X, et al. Regulation of ubiquitin-conjugating enzymes by glutathione following oxidative stress. J Biol Chem 1997;272:28218-26.
50. Luu HH, Zhang R, Haydon RC, et al. Wnt/β-catenin signaling pathway as a novel cancer drug target. Curr Cancer Drug Targets 2004;4:653-71.